Loading clinical trials...
Loading clinical trials...
A Single-dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Recombinant Anti-IL-RAP Humanized Monoclonal Antibody Injection in Chinese Subjects
Conditions
Interventions
IBI3011
IBI3011 Placebo
Locations
1
China
The First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China
Start Date
December 8, 2025
Primary Completion Date
June 7, 2026
Completion Date
June 7, 2026
Last Updated
December 19, 2025
Lead Sponsor
Innovent Biologics (Suzhou) Co. Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions